Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9H3H1
UPID:
MOD5_HUMAN
Alternative names:
Isopentenyl-diphosphate:tRNA isopentenyltransferase; hGRO1; tRNA isopentenyltransferase 1
Alternative UPACC:
Q9H3H1; A1A4X7; Q3T7B5; Q5QPK5; Q5QPK6; Q6IAC9; Q96FJ3; Q96L45; Q9NXT7
Background:
tRNA dimethylallyltransferase, also known as Isopentenyl-diphosphate:tRNA isopentenyltransferase, plays a crucial role in the modification of tRNAs. It catalyzes the transfer of a dimethylallyl group onto adenine at position 37 of tRNAs, facilitating the formation of N6-(dimethylallyl)adenosine. This modification is essential for the proper functioning of both cytosolic and mitochondrial tRNAs, impacting selenoprotein expression significantly.
Therapeutic significance:
The protein's involvement in Combined oxidative phosphorylation deficiency 35, a disorder marked by defective mitochondrial metabolism, underscores its therapeutic significance. Understanding the role of tRNA dimethylallyltransferase could open doors to potential therapeutic strategies for addressing mitochondrial diseases and enhancing mitochondrial function.